Reportstack

Competitor Analysis: Biosimilar and Biosuperior Therapeutic Antibodies 2014

 
Repost This

Naperville, IL -- (SBWIRE) -- 03/14/2014 -- Reportstack, provider of premium market research reports announces the addition of Competitor Analysis: Biosimilar and Biosuperior Therapeutic Antibodies 2014 market report to its offering
The present Competitive Intelligence Report about Biosimilar and Biosuperior Therapeutic Antibodies 2014 provides a competitor evaluation in the field of recombinant monoclonal and polyclonal antibodies in the market, in the pipeline as next generation products and as biosimilar versions as of March 2014.

Marketed antibodies are attractive for companies to create next generation variants and  biosimilar copies because they represent clinically and commercially validated products. New technologies such as Fc engineering, polyclonal mixtures, antibody drug conjugates or bispecific molecules as well as the expiration of patents stimulate the discovery and development of biosimilar and biosuperior/biobetter molecules.

Total sales of recombinant therapeutic monoclonal antibodies originating from companies located in regulated markets reached US$ 75.7 bln in the year 2013. Cumulated 2013 sales of branded therapeutic antibodies approaching patent expiry and, therefore, target of biosimilar substitution, reached US$ 58.6 bln.

The report lists specifically for each target the branded products with their 2013 sales and up-side indications in development, as well as follower, biosuperior and biosimilar antibody drug candidates in development.

2013 Sales data are provided for

Rituxan/MabThera

Arzerra

Zevalin

Gazyva

Herceptin

Perjeta

Kadcyla

Avastin

Zaltrap

Erbitux

Vectibix

XGEVA

Yervoy

Adcetris

Poteligeo

Humira

Enbrel

Remicade

Simponi

Cimzia

Orencia

Nulojix

Ilaris

Arcalyst

Tysabri

Soliris

Xolair

Stelara

Actemra/RoActemra

Benlysta

Lemtrada

ReoPro

Nplate

Prolia

Lucentis

Eylea

Synagis

The report includes a compilation of currently active projects in research and development of biosimilar and biosuperior antibodies against commercially and clinically validated targets:

CD20

Her2

VEGF

TNF

EGF-R

CD52

GPIIb/IIIa

B7.1/B7.2 (CD80/CD86)

IL-6R

Alpha4/beta1/7 integrin

IgE

RSV

RANKL

Complement C5

IL-12/IL-23

Competitor projects are listed in a tabular format providing information on:

Drug Codes,

Target / Mechanism of Action,

Class of Compound,

Company,

Product Category,

Indication,

R&D Stage and

additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

To view the table of contents for this market research report please visit
http://www.reportstack.com/product/151480/competitor-analysis-biosimilar-and-biosuperior-therapeutic-antibodies-2014.html
Contact:
Roger Campbell
contactus@reportstack.com
Naperville
Illinois
United States
Ph: 888-789-6604
###